IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene GALT Ensembl ENSG00000213930 Chromosome 9 Start 34636635 End 34640571
Description Galactose-1-phosphate uridylyltransferase (Gal-1-P uridylyltransferase)(EC 2.7.7.12)(UDP-glucose--hexose-1-phosphate uridylyltransferase) [Source:UniProtKB/Swiss-Prot;Acc:P07902]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :
     HGNC : 4135
     Entrez Gene : 2592
     UCSC : uc003zve.2
     GeneCards : 4135
     RefSeq : NM_000155
     CCDS : CCDS6565.1
     Uniprot : Q96BY1
     Interpro : Q96BY1
     OMIM : 606999
     GeneTests : GALT
     CGAP : GALT

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  36664_at  -0.05  5.84e-1  6.79e-1  -0.16  9.82e-2  1.62e-1
 HG_U133A  203179_at  -0.21  2.31e-5  5.16e-5  1.01  9.74e-14  1.29e-13
 HG_U133_Plus2  203179_at  0.06  2.38e-1  3.20e-1  -0.22  2.90e-3  5.18e-3
 HG_U133_Plus2  232708_at  0.33  7.81e-3  1.64e-2  0.35  2.81e-2  4.22e-2
 HG_U133_Plus2  242734_x_at  0.13  5.01e-1  5.88e-1  -0.12  5.69e-1  6.25e-1
 Stanford  18678  0.38  1.33e-1  3.01e-1  -0.17  6.11e-1  7.94e-1
 Agilent_HS_21.6K  2035  -0.15  1.31e-2  5.60e-2  -0.29  7.81e-6  9.17e-5

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  203179_at  0.01  9.39e-1  9.97e-1  -0.03  8.63e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 36664_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 203179_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 203179_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 232708_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 242734_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 18678    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 2035    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
galt invasive ovarian cancer Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). 11936817 Human
galt epithelial ovarian cancer OBJECTIVE: Previous studies have suggested that high levels of galactose consumption and/or low levels of galactose-I-phosphate uridyl transferase (GALT) activity may result in an increased risk of epithelial ovarian cancer. 11936817 Human
galt ovarian cancer Similarly, some have reported that carriers of the N314D (asparagine at codon 314 replaced by aspartate) GALT polymorphism, which can be associated with low GALT activity, may have a higher risk of ovarian cancer. 11936817 Human
galt borderline ovarian cancer RESULTS: We found no effect of N314D GALT genotype on the risk of borderline ovarian cancer (odds ratio (OR)=0.91; 95% confidence interval (CI)=0.54-1.6) or invasive ovarian cancer (OR=0.78; 95% CI= 0.53-1.2). 11936817 Human
galt invasive ovarian cancer RESULTS: We found no effect of N314D GALT genotype on the risk of borderline ovarian cancer (odds ratio (OR)=0.91; 95% confidence interval (CI)=0.54-1.6) or invasive ovarian cancer (OR=0.78; 95% CI= 0.53-1.2). 11936817 Human
galt invasive ovarian cancer Neither did we observe a relationship between GALT activity or lactose/galactose intake and risk of borderline or invasive ovarian cancer. 11936817 Human
galt ovarian cancer CONCLUSIONS: Differences in galactose intake and GALT metabolism do not contribute significantly to the risk of ovarian cancer. 11936817 Human
galt borderline ovarian cancer There is some evidence that galactose intake may play a role in the development of borderline ovarian cancer among women who carry the uncommon GALT N314D polymorphism. 11936817 Human
galt carcinoma of the ovary Mutations in the genes that encode for metabolic and detoxification enzymes, such as GALT and GSTM, have been implicated in the pathogenesis of endometriosis and in the progression to carcinoma of the ovary. 11949955 Human
galt ovarian cancer In 1993-1999, the authors conducted a population-based case-control study of ovarian cancer in Hawaii and Los Angeles, California, to examine the hypothesis that reduced GALT activity is associated with an increased risk of ovarian cancer. 12370157 Human
galt ovarian cancer No evidence was found for a dose-response relation between the odds ratios for ovarian cancer and GALT activity or the ratio of lactose intake to GALT activity. 12370157 Human
galt ovarian cancer This study did not support the hypothesis that reduced galactose metabolism is a risk factor for ovarian cancer, although increased GALT activity attenuated the inverse association of oral contraceptive pill use with risk. 12370157 Human
galt ovarian cancer The N314D allele of the GALT gene has been associated with low GALT activity and with an increased risk of ovarian cancer. 12869412 Human
galt epithelial ovarian cancer We screened for the presence of the N314D GALT allele in 891 incident cases of epithelial ovarian cancer and in 364 unaffected female controls. 12869412 Human
galt epithelial ovarian cancer We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer. 12869412 Human
galt ovarian cancer Ovarian cancer cases were also more likely to carry the N314D polymorphism of the GALT gene, generally predisposing to lower GALT activity. 10667469 Human
galt ovarian cancer There was no association between ovarian cancer and GALT except among women with abnormally low GALT who had a non-significant 2.5-fold increased risk of ovarian cancer. 10189050 Human
galt ovarian cancer An increased risk of ovarian cancer in women with abnormally low levels of GALT cannot, however, be ruled out. 10189050 Human
galactose-1-phosphate uridylyltransferase chronic lymphocytic leukemia Galactose-1-phosphate uridylyltransferase activity in chronic lymphocytic leukemia. 233300 Human
galt tumor Unusual isoenzyme patterns for galactose-1-phosphate-uridyltransferase (GALT) and phosphoglucomutase1 (PGM1) were detected in the tumor, compared with normal human fibroblasts and blood cells and isoenzyme patterns from the patient's lymphocytes. 2570483 Human
galt ovarian cancer This study examines galactose-1-phosphate uridyl transferase (GALT) activity in women with a family history of ovarian cancer (FOC) to determine if low GALT activity occurs in women who are at risk for but in whom ovarian cancer has not yet developed. 8055453 Human
galt ovarian cancer A survey of 108 heterozygote women for the classic galactosemia gene, GALT, did not reveal that the carrier state was associated with premature ovarian failure or ovarian cancer. 8405535 Human
galt metastatic lung cancer These data suggest an essential role for E1AF in the activation of the human GalT I gene in highly metastatic lung cancer cells. 15611127 Human
galt cancer To clarify the relationship between glycosyltransferases and sugar chain branch structure, we estimated six glycosyltransferases' activities (N-acetylglucosaminyltransferase (GlcNAcTase)-I, -II, -III, -IV, -V, and beta-1,4-galactosyltransferase (GalT 15835923 Human
galt glioma beta1,4-Galactosyltransferase V Functions as a Positive Growth Regulator in Glioma. beta1,4-galactosyltransferase V (GalT V; EC 2.4.1.38) can effectively galactosylate the GlcNAcbeta1-->6Man arm of the highly branched N-glycans that are characteristic of 16461357 Human
galt glioma Previously, we have reported that the expression of GalT V is increased in the process of glioma. 16461357 Human
galt glioma In this study, the ectopic expression of GalT V could promote the invasion and survival of glioma cells and transformed astrocytes. 16461357 Human
galt glioma Furthermore, decreasing the expression of GalT V in glioma cells promoted apoptosis, inhibited the invasion and migration and the ability of tumor formation in vivo, and reduced the activation of AKT. 16461357 Human
galt tumor Furthermore, decreasing the expression of GalT V in glioma cells promoted apoptosis, inhibited the invasion and migration and the ability of tumor formation in vivo, and reduced the activation of AKT. 16461357 Human
galt glioma Taken together, our results suggest that GalT V functioned as a novel glioma growth activator and might represent a novel target in glioma therapy. 16461357 Human
galt glioma In previous study, we have shown that beta1,4-galactosyltransferase V (GalT V) functions as a positive growth regulator in glioma. 16564504 Human
galt glioma Our results suggested that the down-regulation of the expression of GalT V could promote the expression of cell surface integrin beta1 and subsequently inhibit glioma malignant phenotype. 16564504 Human
galt malignancy The serum level of beta1,4-galactosyltransferase (beta1,4-GalT) is increased in both malignancy and benign diseases. 12851678 Human
galt tumor Galactosyltransferase associated with tumor (GAT) is one of the soluble forms of beta1,4-GalT, and is a marker of ovarian cancer with a high specificity. 12851678 Human
galt ovarian cancer Galactosyltransferase associated with tumor (GAT) is one of the soluble forms of beta1,4-GalT, and is a marker of ovarian cancer with a high specificity. 12851678 Human
galt tumor GAT and normal beta1,4-GalT were both detected in ovarian cancer patients, but only GAT reflected the tumor status. 12851678 Human
galt ovarian cancer GAT and normal beta1,4-GalT were both detected in ovarian cancer patients, but only GAT reflected the tumor status. 12851678 Human
galt tumor In tumor-bearing nude mice, both soluble forms of beta1,4-GalT were released from tumor cells, but the half-life of GAT was far shorter than that of normal beta1,4-GalT. 12851678 Mouse

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.